173.00
+8.13%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About ACRO Biomedical Co
Its shares trade on Taipei Exchange under the ticker 6748.TWO. It has been listed since 27 July 2021. In the fiscal year to 31 December 2025, it reported revenue of TWD 38.3m and a net loss of TWD 82.7m. At that date it held total assets of TWD 1.13bn and shareholders' equity of TWD 1.10bn.
ACRO Biomedical Co., Ltd. develops and produces biomaterial medical devices for human tissue engineering and regenerative medicine. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2021-07-27. The firm is also engaged in product-related international trade and technical services business. The firm is engaged in the provision of collagen scaffolds for tissue engineering. The firm's products mainly include pig skin derived products and pig bone derived products. The firm mainly provides ABCcolla Collagen Bone Graft, ABCcolla Collagen Matrix, ABCcolla Collagen Matrix Powder, ABCcolla Scar Spray and ABCcolla External Aesthetic Restoration Prosthesis.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Jul 2021
- Website
- acrobiomedical.com ↗
Leadership
Pay as last reported
- Mr. Dar-Jen HsiehChairman of the Board, General Manager, since 2014
- Yaoting ZengChief Operating Officer-Asia-Pacific
- Xuyao ChenChief Human Resources Officer, since 2023
- Daren XieGeneral Manager
- Qing'an ChengDeputy General Manager-Finance Division, Head of Finance, since 2020
- Mr. Zhaoyi WeiDeputy General Manager-Product Technology Division
- Minhe WangHead of Accounting, Corporate Governance Officer
- Mr. Chao-Sung ChangDirector
- Mr. Chao-Wang ChenDirector
- Ms. Hung-Hung SungDirector
- Mr. Lu-Yen WangDirector, since 2019
- Mr. Ping-Cheng YangDirector
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ACRO Biomedical's ABCcolla Collagen Bone Graft is a key product in tissue engineering.
- The company's pig skin derived products support regenerative medicine applications.
- ACRO Biomedical's collagen scaffolds are used in tissue engineering globally.
Weaknesses
- ACRO Biomedical's product range is limited to pig-derived biomaterials.
- The company's international trade activities face logistical challenges.
- ACRO Biomedical's technical services business lacks diversification.
Opportunities
- Expanding into the growing Health Care sector in Taiwan.
- Increasing demand for collagen scaffolds in regenerative medicine.
- The firm's ABCcolla products can target new markets in Asia.
Threats
- Competition from other biotechnology firms in the Health Care sector.
- Regulatory changes affecting biomaterial medical devices in Taiwan.
- Potential supply chain disruptions for pig-derived products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.